Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Esophageal Stricture Treatment & Management

  • Author: Kavitha Kumbum, MD; Chief Editor: BS Anand, MD  more...
 
Updated: Apr 27, 2016
 

Medical Care

Traditionally, more emphasis has been placed on mechanical dilatation, and coexistent esophagitis has been relatively ignored. However, several studies have demonstrated that aggressive acid suppression using PPIs is extremely beneficial in the initial treatment of esophageal stricture, as well as long-term management.

A dysphagia score developed by Dakkak et al in a study of 64 patients revealed that the stricture diameter only contributed to 30% of the dysphagia score and that esophagitis and other factors accounted for 70% of the score.[9] A linear association existed between the dysphagia score only when the luminal diameter was less than 5 mm. Overall, the degree of dysphagia was worse with increasing esophagitis independent of the degree of stenosis.[9]

Smith et al showed in a randomized study of 366 patients that omeprazole 20 mg/d was superior to ranitidine 300 mg twice a day in preventing stricture recurrence with redilation rates of 30% and 46%, respectively, at 12 months (P < 0.01).[10]

Marks et al showed that the redilation rate in patients treated with omeprazole 20-40 mg/d was 41% versus 73% in patients treated with ranitidine 150-300 mg twice per day and almost reached significance (P < 0.07).[11]  Moreover, the omeprazole group showed higher rates of dysphagia relief and healing of esophagitis when compared with histamine 2 (H2) blockers.

In contrast, 2 other studies by Swarbrick et al[12] and Silvis et al[13] did not show any significant differences in the redilation rates at 12 and 10 months, respectively.

PPI treatment of patients with esophageal stricture is more cost effective than H2 blocker therapy. Marks et al found that over a 6-month period, the cost of omeprazole therapy was $1744 compared with $2957 with H2 blockers.[11]

H2 blockers have not been shown to be any better than placebo in various trials, and no reliable data on prokinetic agents exist.

Next

Surgical Care

The following discussion concerns the endoscopic and surgical modalities employed for the management of peptic esophageal stricture. The choice of dilator and technique is dependent on many factors, the most important being stricture characteristics. It is also based on other factors, including patient tolerance, operator preference, and experience. No clear consensus on the optimal end point exists. In summary, dilation therapy should be tailored individually.

Endoscopic dilation

Endoscopic dilation dates to the 16th century, when physicians used wax wands for esophageal dilation.[14, 15] The word bougie is derived from Boujiyah, an Algerian city that was the center of the medieval candle trade. Three types of dilators are used, as discussed below.

Mercury-filled bougies, such as Maloney or Hurst dilators, are indicated in uncomplicated strictures with diameters greater than 10-12 mm. They are inexpensive and simple to perform without fluoroscopic guidance. In addition, minimal or no sedation is necessary. Self-bougienage may be performed at home.

Wire-guided polyvinyl bougies, such as Savary-Gilliard and American dilators, are relatively stiff and better suited for longer, tighter, and irregular strictures. The need for fluoroscopy is variable. The range is 5-20 mm, and these dilators are reusable. However, drawbacks include trauma to the laryngeal wall and patient discomfort. American dilators are shorter, less tapered, and impregnated with barium for better fluoroscopic visualization.

Savary dilators appear to be safe and effective in the treatment of esophageal narrowing related to pediatric eosinophilic esophagitis (EoE).[16] In a retrospective study (2004-2015) of 50 pediatric cases of EoE in which 11 cases had esophageal narrowing (22%), 19 dilation sessions in 10 cases resulted in good response in all cases. The esophageal size improved from a median of 7 mm to 13.4 mm. Although longitudinal esophageal tear occurred in all cases, no esophageal perforation or chest pain was reported.[16] The investigator noted that a combination of dilation with dietary or medical intervention is required in managing these patients.

Through-the-scope (TTS) balloon dilators are used through the endoscope, and they allow for direct visualization. These are relatively expensive and not reusable. Fluoroscopy is not mandatory, but it is useful in difficult cases. However, studies conflict about the benefits of balloon dilators compared with Savary dilators.

Two separate retrospective institutional studies indicate that fluoroscopic balloon dilatation (FBD) is safe and effective for treating, respectively, esophageal anastomic stricture after surgical repair and caustic esophageal stricture.

In Thyoka et al's review of 12-years of data (1999-2011) from 103 consecutive patients with esophageal anastomotic stricture following surgical repair who underwent 378 FBD sessions, 93 patients (90%) achieved symptomatic relief after a single session (n=44; 47%) or after multiple sessions (n=49; 53%).[17] Of 10 patients who underwent more procedures, 3 had stent placement, 3 had stricture resection, and 4 had esophageal reconstruction. No deaths were reported, but there were 4 esophageal perforations following FBD.[17]

In Uygun et al's review of 8 years of data (2004-2012) from 38 children who underwent FBD for caustic esophageal stricture, 369 FBD sessions were successful overall.[18] Patients who underwent FBD earlier following caustic ingestion had significantly faster and shorter treatment than those who underwent the procedure later after caustic ingestion. In addition, children with shorter esophageal strictures also had significantly shorter FBD treatment than those who had longer esophageal strictures. No deaths were reported, but 5 patients suffered 6 esophageal perforations, which were managed with conservative therapy.[18]

In a prospective, randomized study with 17 patients in each arm comparing balloon dilators with Savary dilators performed over a 2-year period, with the end point being 45F, stricture recurrence was similar in the first year but lower in the second year for balloons, fewer sessions were needed for balloons (1.1 sessions +/- 0.1 versus 1.7 sessions +/- 0.2), and less procedural discomfort occurred (P < 0.05).[19]  Both devices were effective in relieving dysphagia.

Another prospective, randomized study by Scolapio et al that included 251 patients with peptic strictures found that Schatzki rings did not show any differences in complications, the degree of immediate relief, or the time to recurrent dysphagia.[20]

General rules of esophageal dilation

Conside the following:

  • Many authors have questioned the need for mandatory fluoroscopy, and no published data exist to advocate safety of fluoroscopy. However, one may consider using fluoroscopy in complicated strictures, especially in guiding the blind passage of a guidewire.
  • Rule of 3s: The first bougie passed should be approximately equal to the estimated diameter of the stricture. Pass no more than 3 consecutive bougies of progressively increasing size after the first one that meets moderate resistance during any one dilation session. The rule of 3s has been questioned because of a lack of data verifying the increased efficacy or safety if one adheres to this rule. This rule was formulated for dilation using mercury-filled bougies resulting in dilation no greater than 1.3 mm in one session. However, polyvinyl dilators may not provide adequate tactile perception to follow this rule.
  • A study by Kozarek et al showed only one perforation in 400 patients dilated with polyvinyl dilators to greater than 2 mm in one session. [21]
  • Balloon dilators frequently dilate greater than that prescribed by the rule of 3s without any increased risk of complications.

No consensus exists regarding the end point of esophageal dilation for peptic strictures. Most patients experience complete relief when dilated to 40-54F. Therefore, using this end point as a benchmark is recommended. Thus, in summary, the extent of the dilatation should be individualized based on symptomatic response and technical difficulty encountered during therapy.

Intralesional steroid injection

Limited anecdotal data exist showing that intralesional steroid injection of peptic strictures may be beneficial. The mechanism is unclear; it may inhibit collagen formation and enhance collagen degradation, thus increasing stricture compliance.[22]

Triamcinolone 10 mg/mL in 0.5 mL aliquots was injected in 4 quadrants in 2 patients with a successful outcome as reported by Kirsch et al.[23]

Lee at al showed a higher rate of achieving greater luminal diameters and duration between dilations in a nonrandomized cohort of patients with strictures of varying etiologies.[24] Similar results were obtained by Kochhar et al in 71 patients, although 8 injections of 20 mg of triamcinolone in 0.5-mL aliquots were given at the proximal margin and into the stricture itself.[25]

A randomized prospective trial of Savary dilation with or without intralesional steroids was conducted in 42 patients by Dunne et al[26] ; it demonstrated a decreased need for second dilations in the steroid group (1.95 vs 5.5) at 1 year. Similar results were seen in a study by Ramage et al in 30 patients, but the latter study was also double blinded with a sham group.[27] Two patients (13%) in the steroid group and 9 patients (60%) in the sham group needed repeat dilation over a 12-month period.

Therefore, a trial of steroid injection may be reasonable in patients with benign strictures who experience no significant relief of dysphagia despite repeated dilations and aggressive antireflux therapy. Hishiki et al reported the use of repeated endoscopic dilatation with systemic steroids in a child with severe esophageal anastomotic stricture that did not respond to endoscopic dilatation and local steroid injection of the stricture.[28] At 18 months follow-up,the child remained asymptomatic without any further endoscopic dilations.

Endoscopic stricturoplasty

Two case series described a technique using a needle knife to make 4 quadrant incisions followed by Savary dilation. This was successful in 8 of 8 patients as reported by Raijman et al[29] and 5 of 6 patients as reported by Hagiwara et al.[30]

Pharyngoesophageal puncture

Pharyngoesophageal puncture is a term recently coined by Tang et al to describe the technique of endoscopic dilation of radiation-induced severe or complete pharyngoesophageal strictures.[31] A combination of guide wires, endoscopic balloons, puncture and techniques learned from ERCP were successfully applied in 3 patients with severe/complete stenosis.

Expandable polyester silicone-covered stent

Repici et al presented a case series of 15 patients whose condition had failed endoscopic therapy.[32] A temporary placement of a stent for 6 weeks was successful in 12 patients over a long-term period (mean follow-up, 22.7 [2.6] mo). However, the exact duration of stent placement remains unclear, as strictures can recur following stent removal.[33] Furthermore, a variety of complications have been described following stent deployment.[34, 35] More recently, biodegradable stents have shown some promise in animal studies and were used to treat severe corrosive esophageal stenosis in a child.[36]

In a retrospective multicenter study of 70 patients who underwent fully or partially covered self-expandable stent placement (114 procedures) for benign esophageal diseases (benign refractory esophageal strictures, surgical anastomotic strictures, esophageal perforations, esophageal fistulae, surgical anastomotic leaks), investigators found an overall treatment success rate of 55.7%.[37]  They reported 100% success rates for esophageal perforations, followed by 80% for anastomotic leaks, 71.4% for fistulae, 33.3% for refractory benign strictures, and 23.1% for anastomotic strictures. The investigators suggested that esophageal stenting be considered as a first-line therapy for benign esophageal perforations, fistulae, and leaks.[37]

The role of surgical treatment in peptic stricture remains in dispute. Indications include failed aggressive medical therapy or an unsuitable candidate for aggressive medical therapy. This is usually a rare occurrence in the era of PPI therapy. Various procedures advocated include the following:

  • Esophageal-sparing procedures - Standard antireflux surgery (Nissen total or Belsey partial fundoplication), esophageal lengthening with antireflux surgery (Collis-Nissen or Belsey gastroplasty)
  • Esophageal resection and reconstruction - Gastric or colon interposition or jejunal segment

If the benign peptic stricture is dilatable, an esophageal-sparing operation is performed. Note the following:

  • If the length of the esophagus is normal, standard antireflux surgery and postoperative dilation as necessary is recommended.
  • If the esophagus is short, performing Collis gastroplasty and postoperative dilation as necessary is recommended.
  • If the stricture is undilatable, esophageal resection and interposition is recommended.

In the literature, some anecdotal reports exist of minimally invasive surgery, including laparoscopic transhiatal esophagectomy and laparoscopic Collis gastroplasty with Nissen fundoplication. With continuing advances in technology, whether or not minimally invasive surgery would play a major role in the surgical management of peptic stricture remains to be determined.

Previous
Next

Consultations

Surgical consultation is indicated for esophageal stricture if aggressive medical therapy fails or the patient is an unsuitable candidate for aggressive medical therapy.

Surgical consultation is also indicated if the stricture is malignant and amenable to curative or palliative resection.

Previous
Next

Diet

The usual antireflux precautions and lifestyle modifications should be reinforced, although no published data exist showing that these measures are efficacious in peptic strictures. Note the following:

  • Patients are told to avoid fatty and spicy foods, alcohol, tobacco, chocolate, and peppermint.
  • Patients should eat smaller meals, avoid eating in a hurried fashion, and chew their food well.
  • Patients should be encouraged not to eat at least 2-3 hours before bedtime.
  • Weight reduction should be encouraged.
  • Ill-fitting dentures or poor dentition should be corrected if possible.
Previous
Next

Activity

No specific limitation in activity exists.

Previous
Next

Prevention

Consider the following:

  • Several studies have shown that aggressive acid suppression using PPIs is extremely beneficial in the long-term management of peptic esophageal strictures in terms of stricture recurrence (see Medical Care).
  • Patients must continue to follow antireflux precautions and modify their lifestyle as necessary to complement medical therapy.
  • Reviewing all prescription and over-the-counter medications on a regular basis is important to prevent medication-induced stricture recurrence or worsening.
  • Educate all patients about not taking medications known to cause esophagitis, including over-the-counter medications such as aspirin and nonsteroidal anti-inflammatory drugs.
  • Two studies have shown that the number of stricture dilatations has decreased dramatically in North America since the introduction of PPIs in the market.
  • In a study by Dunne et al, the annual number of dilatations decreased from approximately 120 in the pre-PPI era to 50 in the post-PPI era in Kingston, Ontario. [38]
  • In another study by Ugheoke et al in the United States, the number of dilatations performed in 4-year intervals decreased from 504 in the pre-PPI era to 144 in the post-PPI era in one institution.
  • Computerized databases from 1986-2001 of 2 large community hospitals were analyzed by Guda et al. [39]  The need for stricture dilation peaked in 1994 but dropped significantly from 1998-2001, corresponding to an increase in the use of PPIs from 1995 onward.
Previous
Next

Long-Term Monitoring

Closely follow patients' cases to determine the adequacy of esophageal dilation or surgery in relieving dysphagia and the adequacy of pharmacologic antireflux therapy.

Individualize the interval of follow-up visits.

Recurrent dysphagia or inadequate reflux symptom relief should prompt repeat dilation and more aggressive antireflux therapy as necessary.

Counsel patients with esophageal stricture on an ongoing basis regarding the benefits of antireflux dietary precautions and lifestyle modifications.

Previous
 
 
Contributor Information and Disclosures
Author

Kavitha Kumbum, MD Associate Program Director and Attending Physician, Gastroenterology Fellowship Program, Division of Gastroenterology, Bronx Lebanon Hospital Center, Albert Einstein College of Medicine

Kavitha Kumbum, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, New York Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Additional Contributors

Maurice A Cerulli, MD, FACP, FACG, FASGE, AGAF Associate Professor of Clinical Medicine, Albert Einstein College of Medicine of Yeshiva University; Associate Professor of Clinical Medicine, Hofstra Medical School

Maurice A Cerulli, MD, FACP, FACG, FASGE, AGAF is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American College of Physicians, New York Society for Gastrointestinal Endoscopy, American Gastroenterological Association, American Medical Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Julian Katz, MD Clinical Professor of Medicine, Drexel University College of Medicine

Julian Katz, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Geriatrics Society, American Medical Association, American Society for Gastrointestinal Endoscopy, American Society of Law, Medicine & Ethics, American Trauma Society, Association of American Medical Colleges, Physicians for Social Responsibility

Disclosure: Nothing to disclose.

Acknowledgements

Sandeep Mukherjee, MB, BCh, MPH, FRCPC Associate Professor, Department of Internal Medicine, Section of Gastroenterology and Hepatology, University of Nebraska Medical Center; Consulting Staff, Section of Gastroenterology and Hepatology, Veteran Affairs Medical Center

Disclosure: Merck Honoraria Speaking and teaching; Ikaria Pharmaceuticals Honoraria Board membership

Rajeev Vasudeva, MD, FACG Clinical Professor of Medicine, Consultants in Gastroenterology, University of South Carolina School of Medicine

Rajeev Vasudeva, MD, FACG is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, Columbia Medical Society, South Carolina Gastroenterology Association, and South Carolina Medical Association

Disclosure: Pricara Honoraria Speaking and teaching; UCB Consulting fee Consulting

References
  1. Ahtaridis G, Snape WJ, Cohen S. Clinical and manometric findings in benign peptic strictures of the esophagus. Dig Dis Sci. 1979 Nov. 24(11):858-61. [Medline].

  2. Lawson JD, Otto K, Grist W, Johnstone PA. Frequency of esophageal stenosis after simultaneous modulated accelerated radiation therapy and chemotherapy for head and neck cancer. Am J Otolaryngol. 2008 Jan-Feb. 29(1):13-9. [Medline].

  3. Chen AM, Li BQ, Jennelle RL, et al. Late esophageal toxicity after radiation therapy for head and neck cancer. Head Neck. 2009 Jun 17. epub ahead of print. [Medline].

  4. Pace F, Antinori S, Repici A. What is new in esophageal injury (infection, drug-induced, caustic, stricture, perforation)?. Curr Opin Gastroenterol. 2009 Jul. 25(4):372-9. [Medline].

  5. Zografos GN, Georgiadou D, Thomas D, Kaltsas G, Digalakis M. Drug-induced esophagitis. Dis Esophagus. 2009 Apr 15. [Medline].

  6. Ono S, Fujishiro M, Niimi K, Goto O, Kodashima S, Yamamichi N, et al. Predictors of postoperative stricture after esophageal endoscopic submucosal dissection for superficial squamous cell neoplasms. Endoscopy. 2009 Jun 29. [Medline].

  7. Vega KJ, Chisholm S, Jamal MM. Comparison of reflux esophagitis and its complications between African Americans and non-Hispanic whites. World J Gastroenterol. 2009 Jun 21. 15(23):2878-81. [Medline]. [Full Text].

  8. Liu SY, Xiao P, Li TX, et al. Predictor of massive bleeding following stent placement for malignant oesophageal stricture/fistulae: a multicentre study. Clin Radiol. 2016 May. 71 (5):471-5. [Medline].

  9. Dakkak M, Hoare RC, Maslin SC. Oesophagitis is as important as oesophageal stricture diameter in determining dysphagia. Gut. 1993 Feb. 34(2):152-5. [Medline].

  10. Smith PM, Kerr GD, Cockel R. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Restore Investigator Group. Gastroenterology. 1994 Nov. 107(5):1312-8. [Medline].

  11. Marks RD, Richter JE, Rizzo J. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology. 1994 Apr. 106(4):907-15. [Medline].

  12. Swarbrick ET, Gough AL, Foster CS. Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine. Eur J Gastroenterol Hepatol. 1996 May. 8(5):431-8. [Medline].

  13. Silvis SE, Farahmand M, Johnson JA. A randomized blinded comparison of omeprazole and ranitidine in the treatment of chronic esophageal stricture secondary to acid peptic esophagitis. Gastrointest Endosc. 1996 Mar. 43(3):216-21. [Medline].

  14. de Wijkerslooth LR, Vleggaar FP, Siersema PD. Endoscopic management of difficult or recurrent esophageal strictures. Am J Gastroenterol. 2011 Dec. 106(12):2080-91. [Medline].

  15. Fan Y, Song HY, Kim JH, Park JH, Ponnuswamy I, Jung HY, et al. Fluoroscopically guided balloon dilation of benign esophageal strictures: incidence of esophageal rupture and its management in 589 patients. AJR Am J Roentgenol. 2011 Dec. 197(6):1481-6. [Medline].

  16. Al-Hussaini A. Savary dilation is safe and effective treatment for esophageal narrowing related to pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2016 Apr 21. [Medline].

  17. Thyoka M, Barnacle A, Chippington S, et al. Fluoroscopic balloon dilation of esophageal atresia anastomotic strictures in children and young adults: single-center study of 103 consecutive patients from 1999 to 2011. Radiology. 2014 May. 271(2):596-601. [Medline].

  18. Uygun I, Arslan MS, Aydogdu B, Okur MH, Otcu S. Fluoroscopic balloon dilatation for caustic esophageal stricture in children: an 8-year experience. J Pediatr Surg. 2013 Nov. 48(11):2230-4. [Medline].

  19. Saeed ZA, Winchester CB, Ferro PS. Prospective randomized comparison of polyvinyl bougies and through-the- scope balloons for dilation of peptic strictures of the esophagus. Gastrointest Endosc. 1995 Mar. 41(3):189-95. [Medline].

  20. Scolapio JS, Pasha TM, Gostout CJ. A randomized prospective study comparing rigid to balloon dilators for benign esophageal strictures and rings. Gastrointest Endosc. 1999 Jul. 50(1):13-7. [Medline].

  21. Kozarek RA, Patterson DJ, Ball TJ. Esophageal dilation can be done safely using selective fluoroscopy and single dilating sessions. J Clin Gastroenterol. 1995 Apr. 20(3):184-8. [Medline].

  22. Pregun I, Hritz I, Tulassay Z, Herszenyi L. Peptic esophageal stricture: medical treatment. Dig Dis. 2009. 27(1):31-7. [Medline].

  23. Kirsch M, Blue M, Desai RK. Intralesional steroid injections for peptic esophageal strictures. Gastrointest Endosc. 1991 Mar-Apr. 37(2):180-2. [Medline].

  24. Lee M, Kubik CM, Polhamus CD. Preliminary experience with endoscopic intralesional steroid injection therapy for refractory upper gastrointestinal strictures. Gastrointest Endosc. 1995 Jun. 41(6):598-601. [Medline].

  25. Kochhar R, Makharia GK. Usefulness of intralesional triamcinolone in treatment of benign esophageal strictures. Gastrointest Endosc. 2002 Dec. 56(6):829-34. [Medline].

  26. Dunne DP, Rupp T, Rex DK, Lehman GA. Five year follow-up of prospective randomized trial of Savary dilation with or without intra-lesional steroids for benign gastroesophageal reflux strictures [abstract]. Gastroenterology. 1999. 116:A152.

  27. Ramage JI Jr, Rumalla A, Baron TH, et al. A prospective, randomized, double-blind, placebo-controlled trial of endoscopic steroid injection therapy for recalcitrant esophageal peptic strictures. Am J Gastroenterol. 2005 Nov. 100(11):2419-25. [Medline].

  28. Hishiki T, Kouchi K, Saito T, Terui K, Sato Y, Mitsunaga T, et al. Successful treatment of severe refractory anastomotic stricture in an infant after esophageal atresia repair by endoscopic balloon dilation combined with systemic administration of dexamethasone. Pediatr Surg Int. 2009 Jun. 25(6):531-3. [Medline].

  29. Raijman I, Siddique I, Rachal LT. Endoscopic stricturoplasty in the management of recurrent benign esophageal strictures. Gastrointest Endosc. 1999. 49:AB172.

  30. Hagiwara A, Togawa T, Yamasaki J. Endoscopic incision and balloon dilatation for cicatricial anastomotic strictures. Hepatogastroenterology. 1999 Mar-Apr. 46(26):997-9. [Medline].

  31. Tang SJ, Singh S, Truelson JM. Endotherapy for severe and complete pharyngo-esophageal post-radiation stenosis using wires, balloons and pharyngo-esophageal puncture (PEP) (with videos). Surg Endosc. 2009 Jun 11. [Medline].

  32. Repici A, Conio M, De Angelis C, et al. Temporary placement of an expandable polyester silicone-covered stent for treatment of refractory benign esophageal strictures. Gastrointest Endosc. 2004 Oct. 60(4):513-9. [Medline].

  33. Siersema PD. Stenting for benign esophageal strictures. Endoscopy. 2009 Apr. 41(4):363-73. [Medline].

  34. Han Y, Liu K, Li X, Wang X, Zhou Y, Gu Z, et al. Repair of massive stent-induced tracheoesophageal fistula. J Thorac Cardiovasc Surg. 2009 Apr. 137(4):813-7. [Medline].

  35. Thomson A, Baron TH. Esophageal stents: One size does not fit all. J Gastroenterol Hepatol. 2009 Jan. 24(1):2-4. [Medline].

  36. Vandenplas Y, Hauser B, Devreker T, Urbain D, Reynaert H. A biodegradable esophageal stent in the treatment of a corrosive esophageal stenosis in a child. J Pediatr Gastroenterol Nutr. 2009 Aug. 49(2):254-7. [Medline].

  37. Suzuki T, Siddiqui A, Taylor LJ, et al. Clinical outcomes, efficacy, and adverse events in patients undergoing esophageal stent placement for benign indications: a large multicenter study. J Clin Gastroenterol. 2016 May-Jun. 50 (5):373-8. [Medline].

  38. Dunne D, Mercer D, Paterson WG. Decreasing frequency of esophageal dilation for peptic stricture correlates with omeprazole use. Can J Gastroenterol. 1997. 11(suppl A):43A.

  39. Guda NM, Vakil N. Proton pump inhibitors and the time trends for esophageal dilation. Am J Gastroenterol. 2004 May. 99(5):797-800. [Medline].

  40. Agnew SR, Pandya SP, Reynolds RP. Predictors for frequent esophageal dilations of benign peptic strictures. Dig Dis Sci. 1996 May. 41(5):931-6. [Medline].

  41. American Society for Gastrointestinal Endoscopy. Antibiotic prophylaxis for gastrointestinal endoscopy. Gastrointest Endosc. 1995 Dec. 42(6):630-5. [Medline].

  42. Attwood SE, DeMeester TR, Bremner CG. Alkaline gastroesophageal reflux: implications in the development of complications in Barrett''s columnar-lined lower esophagus. Surgery. 1989 Oct. 106(4):764-70. [Medline].

  43. Bell NJ, Burget D, Howden CW. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992. 51 Suppl 1:59-67. [Medline].

  44. Berenson GA, Wyllie R, Caulfield M. Intralesional steroids in the treatment of refractory esophageal strictures. J Pediatr Gastroenterol Nutr. 1994 Feb. 18(2):250-2. [Medline].

  45. Botoman VA, Surawicz CM. Bacteremia with gastrointestinal endoscopic procedures. Gastrointest Endosc. 1986 Oct. 32(5):342-6. [Medline].

  46. Cox JG, Winter RK, Maslin SC. Balloon or bougie for dilatation of benign oesophageal stricture? An interim report of a randomised controlled trial. Gut. 1988 Dec. 29(12):1741-7. [Medline].

  47. Dajani AS, Taubert KA, Wilson W. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA. 1997 Jun 11. 277(22):1794-801. [Medline].

  48. Graham DY, Saeed ZA. Guidewire-assisted esophageal dilation. Gastrointest Endosc. 1991 Nov-Dec. 37(6):650-1. [Medline].

  49. Heller SR, Fellows IW, Ogilvie AL. Non-steroidal anti-inflammatory drugs and benign oesophageal stricture. Br Med J (Clin Res Ed). 1982 Jul 17. 285(6336):167-8. [Medline].

  50. Kadakia SC, Parker A, Carrougher JG. Esophageal dilation with polyvinyl bougies, using a marked guidewire without the aid of fluoroscopy: an update. Am J Gastroenterol. 1993 Sep. 88(9):1381-6. [Medline].

  51. Kuo WH, Kalloo AN. Reflux strictures of the esophagus. Gastrointest Endosc Clin N Am. 1998 Apr. 8(2):273-81. [Medline].

  52. Mamazza J, Schlachta CM, Poulin EC. Surgery for peptic strictures. Gastrointest Endosc Clin N Am. 1998 Apr. 8(2):399-413. [Medline].

  53. Marks RD, Richter JE. Peptic strictures of the esophagus. Am J Gastroenterol. 1993 Aug. 88(8):1160-73. [Medline].

  54. Marks RD, Shukla M. Diagnosis and management of peptic esophageal strictures. Gastroenterologist. 1996 Dec. 4(4):223-37. [Medline].

  55. Meyer GW. Endocarditis prophylaxis for esophageal dilation: a confusing issue?. Gastrointest Endosc. 1998 Dec. 48(6):641-3. [Medline].

  56. Ott DJ, Gelfand DW, Lane TG. Radiologic detection and spectrum of appearances of peptic esophageal strictures. J Clin Gastroenterol. 1982 Feb. 4(1):11-5. [Medline].

  57. Patterson DJ, Graham DY, Smith JL. Natural history of benign esophageal stricture treated by dilatation. Gastroenterology. 1983 Aug. 85(2):346-50. [Medline].

  58. Pungpapong S, Raimondo M, Wallace MB, Woodward TA. Problematic esophageal stricture: an emerging indication for self-expandable silicone stents. Gastrointest Endosc. 2004 Nov. 60(5):842-5. [Medline].

  59. Richter JE. Peptic strictures of the esophagus. Gastroenterol Clin North Am. 1999 Dec. 28(4):875-91, vi. [Medline].

  60. Spechler SJ. AGA technical review on treatment of patients with dysphagia caused by benign disorders of the distal esophagus. Gastroenterology. 1999 Jul. 117(1):233-54. [Medline].

  61. Spechler SJ. American gastroenterological association medical position statement on treatment of patients with dysphagia caused by benign disorders of the distal esophagus. Gastroenterology. 1999 Jul. 117(1):229-33. [Medline].

  62. Spechler SJ. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. N Engl J Med. 1992 Mar 19. 326(12):786-92. [Medline].

  63. Vandenplas Y, Hauser B, Devreker T, Urbain D, Reynaert H. A degradable esophageal stent in the treatment of a corrosive esophageal stenosis in a child. Endoscopy. 2009. 41 Suppl 2:E73. [Medline].

  64. Vollan G, Stangeland L, Soreide JA. Long term results after Nissen fundoplication and Belsey Mark IV operation in patients with reflux oesophagitis and stricture. Eur J Surg. 1992 Jun-Jul. 158(6-7):357-60. [Medline].

  65. Wilcox CM, Alexander LN, Clark WS. Localization of an obstructing esophageal lesion. Is the patient accurate?. Dig Dis Sci. 1995 Oct. 40(10):2192-6. [Medline].

  66. Wilkins WE, Ridley MG, Pozniak AL. Benign stricture of the oesophagus: role of non-steroidal anti- inflammatory drugs. Gut. 1984 May. 25(5):478-80. [Medline].

  67. Zein NN, Greseth JM, Perrault J. Endoscopic intralesional steroid injections in the management of refractory esophageal strictures. Gastrointest Endosc. 1995 Jun. 41(6):596-8. [Medline].

 
Previous
Next
 
Esophageal stricture. Endoscopic appearance of the distal esophagus showing a smooth stricture with a benign appearance.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.